Congress caps insulin at $35—and funds it for the uninsured too
S. 4512 — Affordable Insulin Now Act of 2026 · Filed by John Kennedy (R-LA) · Introduced May 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps insulin cost-sharing at $35 per 30-day supply (or 25% of negotiated price, whichever is lower) for people with private health insurance starting in 2027, and creates a federal reimbursement program to cover the gap between full price and $35 for uninsured individuals. Insured patients and uninsured people who cannot afford insulin benefit; insurers and pharmacy benefit managers face pressure to absorb or negotiate lower prices.
Why we flagged it
The bill's core mechanism is a dual-track price control: capping cost-sharing for insured patients and subsidizing uninsured patients to reach a $35 threshold. It is straightforward healthcare cost regulation, not a hidden carve-out or rider.
What the text implies
- The $35 cap applies only to 'selected insulin products' chosen by each plan, not all insulins—plans retain discretion to limit coverage breadth, potentially steering patients toward cheaper formulations.
- Pharmacy benefit managers (PBMs) are explicitly named as entities whose price concessions count toward the negotiated price calculation, suggesting the bill anticipates PBM rebate structures will be affected.
The full analysis lists 5 implications of this text.
Who stands to gain
diabetes patients (insured and uninsured); community health centers and pharmacies (via federal reimbursement); potentially generic/biosimilar insulin manufacturers (if price pressure shifts market share)